Gapping down
In reaction to disappointing earnings/guidance: ECR -12.4%, (updates on its operations, provides FY16 capex & production guidance; announced that it has commenced an underwritten public offering of 37,500,000 shares of its common stock), AVAV -7.9%, AYI -2.7%
M&A news: HTCH -7.4% (Hutchinson Tech. updates on status of acquisition by TDK Corporation, says the FTC is continuing its review and has not indicated when its review may be completed)
Select EU financial related names showing weakness: LYG -2%, RBS -1.7%, DB -1.7%, CS -0.9%
Other news: LPCN -52.2% (receives CRL from the FDA regarding its NDA for LPCN 1021), ESPR -32.1% (provides clinical development and regulatory update for Bempedoic Acid; on track to initiate global pivotal Phase 3 studies and CVOT in Q4 ), ECR -12.8% (offering of 37.5 mln shares of its common stock at $3.50 per share), ALV -4.9% (confirms in statement to Reuters its involvement in Toyota's (TM) Prius recall), HR -4.1% (prices offering of 8 mln shares of common stock for gross proceeds of $268 mln), ANTH -2.3% (provides clinical program updates for Blisibimod and Sollpura, says positive trends from BRIGHT-SC proof-of-concept study and study will continue), BUFF -1.0% (prices secondary offering of 15 mln shares common stock by selling stockholders at $22/share), SWN -1.0% (commences 75 mln common stock offering)
Analyst comments: AEG -2.2% (downgraded to Underweight from Equal Weight at Barclays)